Skip to main content

Table 1 Estimated average monthly rates of adverse events per 100,000 patients in three time periods

From: Rosiglitazone use and associated adverse event rates in Canada: an updated analysis

 

April 2004–October 2007

November 2007–December 2010

January 2011–December 2012

Average

Min/max

95 % CI

Average

Min/max

95 % CI

Average

Min/max

95 % CI

Adverse events

13.1

2.3/26.9

8.4–20.4

5.6

0.0/12.1

2.3–13.4

10.8

0.0/42.9

2.0–59.2

Serious adverse eventsa

5.9

0.6/21.1

3.1–11.3

3.3

0.0/8.6

1.1–10.4

9.1

0.0/42.9

1.3–62.4

Cardiac adverse eventsb

2.2

0.0/9.2

0.8–6.4

2.1

0.0/6.6

0.5–8.9

5.0

0.0/20.8

0.4–65

  1. aOf the adverse events this row accounts for the serious adverse events
  2. bOf the serious adverse events this row accounts for the cardiac adverse events
Back to article page

BMC Research Notes

ISSN: 1756-0500

Contact us